Home › Trials › NCT07227597

Gocatamig and ifinatamab deruxtecan combined with standard therapy for extensive-stage small cell lung cancer

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Phase1; Phase2 Interventional Merck Sharp & Dohme LLC · NCT07227597

This trial tests whether giving gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy plus immunotherapy, helps people with extensive-stage small cell lung cancer.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment170 (estimated)
Ages18 Years and up
SexAll
SponsorMerck Sharp & Dohme LLC Industry-sponsored
Drugs / interventionsifinatamab, atezolizumab, chemotherapy, radiation, immunotherapy
Locations23 sites (Orlando, Florida and 22 other locations)
Trial IDNCT07227597 on ClinicalTrials.gov

What this trial studies

This is a multi-part Phase 1/2 interventional trial that gives participants combinations of a T‑cell engager (gocatamig) and an antibody‑drug conjugate (ifinatamab deruxtecan, I‑DXd), sometimes together with standard carboplatin/etoposide and atezolizumab. In Part A participants are assigned to one of two arms per the investigator, while in Part B participants are assigned to one arm and randomized among several combination arms for induction and maintenance therapy. The study will measure safety, recommended dosing, and early signs of anti‑tumor activity using standard response criteria. Treatments are administered at participating U.S. cancer centers with regular clinic visits for infusions and monitoring.

Who should consider this trial

Good fit: Ideal candidates are adults with histologically confirmed extensive‑stage small cell lung cancer who meet protocol criteria, including some cohorts that require completion of 3–4 cycles of first‑line platinum/etoposide plus PD‑1/L1 therapy without radiologic progression.

Not a fit: Patients with radiographic disease progression, multiple prior systemic lines for ES‑SCLC, or who cannot tolerate chemotherapy or immunotherapy are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, the combination could improve tumor control and lengthen progression‑free and overall survival compared with current standard options.

How similar studies have performed: Antibody‑drug conjugates and T‑cell engagers have shown promising signals in early trials for lung cancers, but combining gocatamig with I‑DXd in ES‑SCLC is a novel approach that has not yet been proven.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has a histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC)
* For participants receiving gocatamig + ifinatamab deruxtecan (I-DXd) in maintenance only:

  * Completed 3 to 4 cycles of platinum + etoposide chemotherapy with concurrent approved anti-programmed cell death 1/Ligand 1 (anti PD-1/L1) as first line (1L) treatment of ES-SCLC within 6 weeks prior to enrollment
  * No radiological disease progression per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
  * No other prior systemic ES-SCLC therapy allowed
  * Rechallenge therapy counts as an additional line and leads to exclusion
* For participants receiving gocatamig + I-DXd in induction and maintenance, or gocatamig + I-DXd in induction followed by gocatamig + atezolizumab in maintenance, or carboplatin + etoposide + atezolizumab in induction followed by atezolizumab in maintenance: No prior systemic ES-SCLC treatment allowed
* Applicable to all participants: prior limited-stage small cell lung cancer (SCLC) is allowed if \> 6 months have passed since the end of previous therapy and progression
* Must be able to provide a pretreatment archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated
* Measurable disease by RECIST 1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if growth has been shown in such lesions since the completion of radiation

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
* Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, current ILD, ILD that cannot be ruled out by imaging at screening, or suspected ILD
* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
* Has history of clinically significant intracranial bleeding or spinal cord bleeding
* Has active neurologic paraneoplastic syndrome
* Has history of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF), and/or uncontrolled cardiac arrhythmia within 6 months before the first dose of study intervention
* Has other uncontrolled or significant protocol specified cardiovascular disease
* Has history of arterial thrombosis within 6 months before the first dose of study intervention
* Has chronic liver disease
* Has history of allogeneic tissue/solid organ transplant
* Has history of leptomeningeal disease
* Is infected with human immunodeficiency virus (HIV) and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Has known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has major surgery within 4 weeks or minor surgery within 2 weeks of allocation/randomization (or first dose), or is anticipated to require a major surgical procedure during the study

Where this trial is running

Orlando, Florida and 22 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Small Cell Lung Cancer Extensive Stage
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.